Results 11 to 20 of about 1,701 (232)

Pitolisant-associated mania – a case report [PDF]

BMC Neurology
Background Narcolepsy is a chronic neurological disorder treated with medications that promote wakefulness. Pitolisant, a histamine H3 receptor inverse agonist, is used to reduce excessive daytime sleepiness.
Maximilian Zoltek, Richard Ågren
doaj   +2 more sources

Pitolisant Inhibits Alcohol Drinking and Improves Withdrawal Negative Affect Through Lateral Habenula Histaminergic Signaling in Mice. [PDF]

CNS Neurosci Ther
Pitolisant, an FDA‐approved H3R antagonist, counteracts the rewarding and sedative effects of ethanol, reduces alcohol intake, and alleviates the negative affect during withdrawal. This might occur via the antagonism of presynaptic autoreceptors and heteroreceptors H3Rs in the lateral habenula, thereby activating the H2R/p‐CREB/BDNF signaling and ...
Zhao Y, Fu Y, Liu T, Yang Z, Yang Z, Chen B, Zhou L, Yang J, Chen D, Han X, Tang Y, Ye JH, Miao CY, Fu R.   +13 more
europepmc   +4 more sources

Pitolisant: Pediatric First Approval

Pediatric Drugs, 2023
Pitolisant (WAKIX®), a histamine H3 receptor antagonist/inverse agonist that has been developed by Bioprojet Pharma, is approved in the EU and USA and elsewhere for use in adults with narcolepsy with or without cataplexy. In February 2023, based on clinical data in patients aged 6 to < 18 years, pitolisant received its first approval in adolescents and
Susan J. Keam
openalex   +4 more sources

Quantification of Pitolisant: A RP - HPLC study

YMER Digital, 2022
Objective An attempt was made to develop a simple, isocratic and robust reverse phase high performance liquid chromatographic method for Pitolisant. Material and methods An Inertsil octa decyl silane column and photo diode array detector were employed for the quantification of Pitolisant at 268 nm using a mobile phase consisting of acetonitrile and 0.1
Sowjanya Gummadi, Rajya Lakshmi Nimmagadda   +1 more
openalex   +2 more sources

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]

EClinicalMedicine
Summary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin, Philippe Lehert, Raoua Ben Messaoud, Marie Joyeux-Faure, Christian Caussé, Jerryll Asin, Ferran Barbé, Maria R. Bonsignore, Winfried Randerath, Johan Verbraecken, Sonya Craig, Yves Dauvilliers   +11 more
doaj   +2 more sources

Increased Sensitivity of Mice Lacking Extrasynaptic δ-Containing GABAA Receptors to Histamine Receptor 3 Antagonists [PDF]

Frontiers in Pharmacology, 2020
Histamine/gamma-aminobutyric acid (GABA) neurons of posterior hypothalamus send wide projections to many brain areas and participate in stabilizing the wake state.
Shamsiiat Abdurakhmanova, Milo Grotell, Jenna Kauhanen, Anni-Maija Linden, Esa R. Korpi, Pertti Panula   +5 more
doaj   +3 more sources

Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis [PDF]

Neuropsychopharmacology Reports
Aim Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question.
Yasufumi Nishii, Kenji Sakuma, Shun Hamanaka, Nakao Iwata, Taro Kishi   +4 more
doaj   +2 more sources

Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis [PDF]

BMC Neurology
Background As a rare sleep disorder, narcolepsy is treated with various therapeutic options. This article systematically analyzes the efficacy and safety of novel approved wake-promoting drugs.
Zian Yan, Jiwei Li, Yixin Yu, Shenghan Qiu, Bing Wang, Jiyou Tang   +5 more
doaj   +2 more sources

Pentylenetetrazol-induced seizures and brain neuroinflammation markers under conditions of pitolisant and pioglitazone use [PDF]

Journal of Education, Health and Sport
The purpose of the study was to investigate the dynamics of seizure activity and markers of neuroinflammation in kindled rats under conditions of individual and combined use of pitolisant and pioglitazone.
O. Yehorenko, M. Pervak
doaj   +3 more sources

H_3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice [PDF]

, 2016
The use of atypical antipsychotic drugs like olanzapine is associated with side effects such as sedation and depression-like symptoms, especially during the initial period of the use.
Bednarski, Marek, Kieć-Kononowicz, Katarzyna, Kotańska, Magdalena, Kołaczkowski, Marcin, Kuder, Kamil, Olczyk, Adrian, Pytka, Karolina, Rak, Aleksandra, Sapa, Jacek, Żmudzka, Elżbieta   +9 more
core   +3 more sources